Pacific Edge contract with US vets positive, though value remains to be seen

Pacific Edge contract with US vets positive, though value remains to be seen
Sophie Boot
By Sophie Boot March 7 (BusinessDesk) - Pacific Edge's supply deal with the US Veterans Administration is positive news but it's still unclear how much benefit the bladder cancer test maker will get from the contract, brokerage First NZ Capital said. The brokerage has an 'outperform' rating on Pacific Edge and a target price of 60 cents per share, above its current price of 47.5 cents. Pacific Edge shares jumped after the Dunedin-based company announced in late February that it had signed a federal supply schedule agreement with the VA...